Kite must pay $1.2bn for infringing CAR-T patent

09-04-2020

Kite must pay $1.2bn for infringing CAR-T patent

Sundry Photography / Shutterstock.com

A California federal judge has issued a final award of $1.2 billion in damages to Bristol-Myers Squibb subsidiary Juno Therapeutics in its patent infringement dispute with Gilead’s Kite Pharma.


Kite Pharma, Juno Therapeutics, BMS, Bristol-Myers Squibb, Gilead, Sloan Kettering, patent, infringement, CAR-T

LSIPR